Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/25/23
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 10/23/23
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?Zacks Investment Research • 10/17/23
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson DiseaseGlobeNewsWire • 10/16/23
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)GlobeNewsWire • 10/14/23
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)GlobeNewsWire • 10/09/23
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023GlobeNewsWire • 10/05/23
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 09/25/23
Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/08/23
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate UpdateGlobeNewsWire • 08/03/23
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate UpdateGlobeNewsWire • 07/27/23
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate StrategyGlobeNewsWire • 07/12/23
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)GlobeNewsWire • 07/06/23
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/07/23
Ultragenyx, Mereo shares gain after positive results from study of bone disorder treatmentMarket Watch • 06/06/23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)GlobeNewsWire • 06/05/23